Semaglutide denied for missing prior authorization by Anthem?

Anthem's specific coverage criteria for semaglutide are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Anthem Requires Prior Authorization for Semaglutide — and How to Succeed on Appeal

Anthem's prior authorization (PA) process for semaglutide is a gatekeeping step that requires clinical documentation before coverage begins. A PA denial at the initial submission stage — or on appeal of a denial — typically means the documentation provided did not satisfy every criterion in Anthem's clinical policy, even if semaglutide is clinically appropriate for you. The appeal process is an opportunity to resubmit with a complete, criterion-by-criterion documentation package.

## Why PA Denials Are Winnable

Prior authorization criteria are written requirements, not subjective judgments. When documentation addresses every criterion explicitly and the chart supports coverage, approvals follow. The most common reason PA appeals succeed is simply that the original submission was incomplete — the prescriber's office submitted a brief note rather than a structured letter, or a required document (prior-treatment history, lab result, diagnosis confirmation) was missing.

## Your Federal Appeal Rights

• ERISA §503 / ACA §2719 internal appeal: You have the right to a full-and-fair review of any PA denial. Request the specific Anthem clinical policy and the specific criterion or criteria Anthem found unmet. This information is required to be disclosed to you.
• Peer-to-peer review: Before or during the formal appeal, your prescriber may request a peer-to-peer call with Anthem's medical director. This is often the fastest path to reversal for PA denials.
• External review (ACA §2719): Available after the final internal adverse determination. File within four months.
• Expedited review: Available when standard timelines would seriously jeopardize your health.

## What to Gather

1. Anthem's clinical policy (medical policy bulletin) for semaglutide — the exact document Anthem's reviewer used. Download from Anthem's provider or member portal, or request it in writing. 2. FDA-approved prescribing information — confirms the approved indication and clinical use context. 3. Complete diagnosis documentation: Chart notes, specialist consultation notes, relevant lab results with dates, and ICD codes. 4. Prior-treatment history: For each drug or therapy Anthem's policy requires you to have tried, document the drug name, dates of use, and clinical outcome or reason for discontinuation. Pharmacy records are strong supporting evidence. 5. Prescriber's structured medical-necessity letter: Should address each PA criterion in order, using chart-specific language for every response. Generic letters are consistently less effective than criterion-mapped letters. 6. Any applicable specialist opinion — an endocrinologist or obesity medicine specialist's letter adds independent clinical weight.

## Criteria-Mapping Structure

Obtain the Anthem clinical policy. Number each criterion. In the prescriber letter, use the same numbers and respond to each one with the specific chart fact that satisfies it — date of diagnosis, name of prior drug with dates, clinical note characterizing severity. Submit the clinical policy as Exhibit A and the prescriber letter as Exhibit B, so the reviewer can cross-reference.

## Key Argument

PA criteria are satisfied, not argued around. A complete submission that maps every criterion to a specific chart fact leaves the reviewer with no clinical basis to deny — only an administrative one, and those are overturned at external review.